Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

yes, imo this is a very good statement (apart from the delay in orders!) and in true nhs style. But I believe that once the first ordes are received the snowball will start rolling.
A great buying opp'. DYOR.

Glad I didn't panic and held my nerve, hope I can free to funds soon to buy again at these prices.

Minor setback I reckon..Company & products still good. it's always going to be difficult dealing with the NHS but when the sales do start coming in the SP will rocket (imho) I'm holding on :)

I have now joined in--picked up afew this morning. Great prospects but patience needed.

Hi all.

I have just go into this one. Ive been looking at it for a while & decided to jump in before it takes off. Looks like the recent drop was down to a profit warning if orders were not placed with them by 31st december 2004. They were not placed but it looks like 2005 will be good for DEMG.

Here is a recent trading statement made by the company,


Deltex Medical Group PLC
16 December 2004

Deltex Medical Group plc


Trading update


16 December 2004: Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the AIM listed haemodynamic monitoring company, today announces an update on
expected trading performance in advance of the preliminary announcement of its
results for the year ending 31 December 2004.

The Company has made considerable progress in raising awareness of the clinical
and economic benefits of routine haemodynamic optimisation using its CardioQ(TM)
system. This progress has accelerated since 24 September 2004 when the Company
announced both the results of a new clinical study in Worthing and the results
of a post-procurement audit of wide-scale use of the CardioQ at the Medway
Maritime Hospital ('Medway'). Together with the significant body of clinical
evidence, these new results meant the Company could now demonstrate clearly to
both doctors and hospital administrators that using the CardioQ as a standard of
care delivers more cost effective, better quality of care for large numbers of
patients.

Our discussions in hospitals indicate that iincreasing numbers of anaesthetists,
surgeons and senior hospital managers have now recognised the importance of
implementing this change in the management of higher risk surgical patients. The
Company is currently working to conclude sales negotiations with 14 hospitals in
the UK National Health Service ('NHS') who are planning to implement routine,
wide-scale use of the Company's products. The Company has already reached
agreement in principle with a further six NHS hospitals which they will work
with the Company towards wide-scale purchase of the Company's product(s),
subject to focused local evaluations scheduled to be undertaken in the first
quarter of 2005. In addition clinicians at over 20 more NHS hospitals support
the adoption of CardioQ as a standard of care into priority uses of hospital
budgets in the NHS financial year beginning 1 April 2005.

In the USA, Deltex Medical has been working in partnership with the Veteran's
Administration (VA) Hospital in San Antonio to undertake a similar audit to that
concluded earlier in the year at Medway. The doctors at this site have
demonstrated to their own satisfaction that routine haemodynamic optimisation
delivers the clinical benefits and length of stay improvements in the setting of
the VA system and have already begun to modify treatment protocols based on
their experience. From 1 November 2004 haemodynamic optimisation was adopted as
a standard of care at the VA Hospital in San Antonio and requisitions have been
raised internally by the hospital to fund the increased numbers of monitors and
probes required to enable full implementation. These requisitions are supported
by the hospital's senior administrators.

The Company is also working with its distributor partners in Europe to establish
'flagship' hospital-wide adoption sites in five countries. These sites are
aiming to demonstrate over the first half of 2005 that the clinical, economic
and efficiency benefits demonstrated through the Medway post-procurement audit
can be achieved in their individual healthcare environments.

In order for the Company to report sales for the year ending 31 December 2004 in
line with current market expectations, it would be necessary for the majority of
the fifteen identified hospitals in the UK and USA to complete their internal
procurement processes and place an order with the Company in time for delivery
before 31 December. The Directors now consider it likely that several or
possibly even all of these hospitals will be unable to meet the timeframes which
the Company has proposed and that the Company's sales for the year will be lower
than market expectations by corresponding amounts. However, the Directors
remain confident that these orders will be forthcoming in the first half of
2005. The Directors continue to believe that the Company is well positioned to
make haemodynamic optimisation using its products a standard of care in a number
of major markets.




For further information, please contact:-

Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman
nigel.keen@deltexmedical.com


regards,

wilbs

Below are two more RNS announcements made recently.

Deltex Medical Group PLC 20 December 2004 Deltex Medical Group plc Additional Listing Deltex Medical Group plc (the 'Company') has been notified today that certain of its European distributors have acquired 500,000 ordinary shares of 1p each at a price of 211/4 pence per share as the result of the exercise of an option over 500,000 shares granted on 31 December 2003. Accordingly, application has been made for these shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 23 December 2004. For a period of eighteen months following admission of these new ordinary shares, the European distributor has undertaken not to sell or dispose of any of these Ordinary Shares without the express written permission of the Company and that, in the event that it does sell or dispose of any of these shares in this time period, it will do so through the Company's broker from time to time (subject to certain limited exceptions). Following this additional listing, the number of shares in issue will be 69,083,253.
-----------------------------------------------------------------------------

Deltex Medical Group PLC 08 December 2004 Deltex Medical Group plc Appointment of German distributor for CardioQ(TM) 8 December 2004: Deltex Medical Group plc ('Deltex Medical'), the haemodynamic monitoring company, announces the appointment of P. J. Dahlhausen & Co. GmbH (Dahlhausen) as its distributor partner for CardioQ in Germany with immediate effect. Dahlhausen, based in Cologne, has manufactured and distributed medical devices throughout Germany for 150 years and has a strong reputation with hospitals across the country. They have a substantial field sales and clinical support force of 25 people covering all German hospitals. Germany's healthcare system is emerging from a period of significant reorganisation following the implementation of new funding and reimbursement systems aimed at addressing systemic cost and efficiency issues. Prior to entering into this arrangement, Dahlhausen's senior management asked their sales and marketing team to undertake a detailed evaluation of the potential for haemodynamic optimisation in Germany. This evaluation concluded that the proven economic and clinical benefits derived from the use of Deltex Medical's CardioQ monitor fit well with the new German healthcare regime. Dahlhausen also believes that the novel sales approaches developed by Deltex Medical for the UK market can effectively be tailored to fit the specific characteristics of the German market place. Chief Executive, Andy Hill commented: 'Germany is the final European territory in our strategic sales and distribution roll-out of CardioQ. While Germany represents the biggest medical technology market in Europe, it is also one of the more complex environments to do business in. Dahlhausen have demonstrated that they clearly understand the difficulties of their market and have the resources, human and intellectual, to create a successful platform from which to launch our products. I believe that our collaboration with Dahlhausen will help German doctors and healthcare managers to deliver to patients undergoing moderate and major surgery the highest quality care in the most cost effective manner.' Peter Dahlhausen, Managing Director of P. J. Dahlhausen & Co. GmbH commented: 'I am delighted that Dahlhausen will be working with Deltex Medical and look forward to developing a successful long-term relationship with the company. Feedback about the CardioQ from the sales and marketing team and our customers has been consistently positive and I believe we have a real opportunity to establish haemodynamic optimisation, using the CardioQ, as a standard of care for moderate and major surgery in Germany. Our initial focus will be on establishing wide-scale use of the CardioQ in selected key hospitals.'


Happy reading

wilbs

Strong buys this morning, i`m suprised the price hasn`t ticked up based on this strong demand. Would like to see a move up by the end of the day. D

Good strong buys. 118,222 buys compared to 7,500 sells. Lets hope we see a rise but imho I thing it may be quiet till 2005 when we will start to see some orders come in.

wilbs

wilbs - Thanks for excellent posts - wonder how these RNS slipped past MoneyAM or did I have my eyes shut - If not a Merry Christmas I do think we are in for a Very Happy New Year

No probs oakapples142. I have now put DEMG onto my e-mail list with uk wire so when more RNS are realeased I will be alerted my e-mail, I will also post them on this thread if they already have not done so.
I plan to have a scout rount the net over xmas so will keep you all updated.

wilbs

How do you do that wilbs? I'd love to get an email saying "stock XXX has just had
an RNS/ AFX/ PRNW news item" so I can go and check. This would save an awful lot of
time repeatedly examining the news items list of each company I'm interested in.

My current broker (comdirect) doesn't do this.

wilbs - Thanks again how very kind - I trust and hope that you get all you need and deserve from Santa

Arf Dysg

Goto www.uk-wire.com

You will see an 'Alerts by e-mail" header. Click on that and it will take you to another page. Simply click on 'REGISTER HERE' and follow the instructions. You can put as many companies in as you like.

Hope its some help.

Regards

wilbs

Hi oakapples142,

I dont think santa can give me what I want this year. Maybe he will look afer us all next year! Have you been holding DEMG long? I got in at 27p.

wilbs

I wont pursue the Santa bit ! - Bought DEMG on 7 Oct at 28.50p so its owing me some ! - I am confident on this one - NHS bound to drag its feet - Germany and gradually the rest of Europe is what I am hoping for.

I think we will see alot from DEMG in 2005. They will be pushing forward and getting them contracts in. Europe will be great but if they get their foot in the door in america then the potential surely must be fantastic!!

wilbs

Interestingly there has only been one recorded sale to-day at 8.01am and yet not rise in SP. MMs must have plenty in hand following them shaking the trees a week or so ago. We could do with a institution buy to give us a merrier Christmas

Just realeased.

Deltex Medical Group PLC
23 December 2004


Deltex Medical Group plc

Directors' Shareholdings

Deltex Medical Group plc ('the Company'), the AIM listed haemodynamic monitoring
company, announces that it has today issued a total of 394,340 new ordinary
shares of 1p each in the Company to certain non-executive directors at a price
of 261/2 pence per share based on yesterday's closing mid-market price .

The three non executive directors named below have elected to take shares in
lieu of a cash payment as remuneration for their services to the Company.

Accordingly, application has been made for these shares to be admitted to
trading on AIM. The shares rank pari passu with the existing issued shares of
the Company and dealings are expected to commence on 4 January 2005. Following
this additional listing, the number of shares in issue will be 69,477,593.

Following this issue, the director's beneficial interests are as follows:


Name of Director Number of shares Holding of shares % of enlarged issued
issued following issue share capital

Nigel Keen (1) 94,340 3,679,917 5.30%
Dr Edwin Snape (3) 215,094 3,095,019 4.45%
Peter Smedvig (2) 84,906 1,029,384 1.48%
Andy Hill - 42,857 0.06%
Ewan Phillips - 465,714 0.67%
George Flouty - 164,285 0.24%

Total 394,340 8,477,176 12.20%

(1) Includes 589,700 shares held as trustee and executor of Pauline Thomas
Charity Will Trust.

(2) Includes shares held as director of Peder Smedvig Capital AS.

(3) Includes shares held as a director of New England Partners and
associated companies.

For further information, please contact:-

Deltex Medical Group plc 01243 774 837



They have taken the shares instead of a cash payment.Must be good news!!


wilbs

Shows great faith in their company--good luck to all of us for 2005!

I'll drink to that moneyplus.

Cheers!!!

wilbs